InsiderTrades.com logo

CNSP Insider Trading

Insider Ownership Percentage: 0.01%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

CNS Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at CNS Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CNS Pharmaceuticals Share Price & Price History

Current Price: $2.18
Price Change: ▲ Price Increase of +0.05 (2.35%)
As of 04/10/2026 05:00 PM ET

This chart shows the closing price history over time for CNSP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

CNS Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2023Christopher DownsCFOBuy0$38,100.00$0.001View SEC Filing Icon  
8/16/2023John M ClimacoCEOBuy0$54,000.00$0.001View SEC Filing Icon  
4/19/2023Jerzy GumulkaDirectorBuy0$51,000.00$0.00View SEC Filing Icon  
4/17/2023Christopher DownsCFOBuy0$96,000.00$0.00View SEC Filing Icon  
4/12/2023John M ClimacoCEOBuy0$20,700.00$0.001View SEC Filing Icon  
4/10/2023Jerzy GumulkaDirectorBuy0$22,200.00$0.00View SEC Filing Icon  
3/27/2023Waldemar PriebeMajor ShareholderSell0$32,700.00$0.005View SEC Filing Icon  
3/24/2023Waldemar PriebeMajor ShareholderSell0$32,400.00$0.005View SEC Filing Icon  
3/22/2023Waldemar PriebeMajor ShareholderSell0$32,400.00$0.006View SEC Filing Icon  
3/20/2023Waldemar PriebeMajor ShareholderSell0$32,400.00$0.006View SEC Filing Icon  
3/17/2023Waldemar PriebeMajor ShareholderSell0$33,900.00$0.006View SEC Filing Icon  
3/15/2023Waldemar PriebeMajor ShareholderSell0$36,600.00$0.007View SEC Filing Icon  
3/13/2023Waldemar PriebeMajor ShareholderSell0$39,000.00$0.007View SEC Filing Icon  
3/10/2023Waldemar PriebeMajor ShareholderSell0$38,700.00$0.007View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for CNS Pharmaceuticals (NASDAQ:CNSP)

14.02% of CNS Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNSP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

CNS Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Ikarian Capital LLC45,830$0.24M0.0%N/A7.392%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC13,524$71K0.0%N/A2.181%Search for SEC Filing on Google Icon
8/14/2025Armistice Capital LLC406,000$0.34M0.0%N/A90.222%Search for SEC Filing on Google Icon
2/18/2025Connective Capital Management LLC280,055$34K0.0%N/A0.487%Search for SEC Filing on Google Icon
2/17/2025Citadel Advisors LLC321,874$39K0.0%N/A0.560%Search for SEC Filing on Google Icon
2/14/2025Jane Street Group LLC419,737$51K0.0%+1,712.3%0.730%Search for SEC Filing on Google Icon
2/14/2025Integrated Wealth Concepts LLC250,000$30K0.0%N/A0.435%Search for SEC Filing on Google Icon
2/13/2025XTX Topco Ltd294,919$36K0.0%N/A0.513%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC387,064$47K0.0%+90.5%0.673%Search for SEC Filing on Google Icon
2/7/2025Wealthfront Advisers LLC216,046$26K0.0%N/A0.376%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC94,246$34K0.0%+616.6%0.795%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC122,000$0.16M0.0%N/A1.965%Search for SEC Filing on Google Icon
1/17/2024Smith Anglin Financial LLC50,000$64K0.0%N/A0.952%Search for SEC Filing on Google Icon
8/7/2023Acadian Asset Management LLC22,292$49K0.0%N/A1.000%Search for SEC Filing on Google Icon
7/12/2023FSM Wealth Advisors LLC16,334$38K0.0%N/A0.732%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
CNS Pharmaceuticals logo
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Read More on CNS Pharmaceuticals

Today's Range

Now: $2.18
Low: $2.10
High: $2.18

50 Day Range

MA: $3.05
Low: $2.13
High: $5.41

52 Week Range

Now: $2.18
Low: $2.06
High: $34.80

Volume

10,985 shs

Average Volume

41,432 shs

Market Capitalization

$1.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Who are the company insiders with the largest holdings of CNS Pharmaceuticals?

CNS Pharmaceuticals' top insider shareholders include:
  1. Waldemar Priebe (Major Shareholder)
  2. Christopher Downs (CFO)
  3. John M Climaco (CEO)
  4. Jerzy Gumulka (Director)
Learn More about top insider investors at CNS Pharmaceuticals.

CNS Pharmaceuticals Active Insiders

Christopher Downs
Christopher Downs (Age 48)
CFO